Indoco Remedies has reported results for fourth quarter and year ended March 31, 2022.
The company has reported a rise of 62.06% in its net profit at Rs 40.37 crore for the quarter under review as compared to Rs 24.91 crore for the same quarter in the previous year. Total income of the company increased by 33.36% at Rs 409.17 crore for Q4FY22 as compared Rs 306.82 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 61.80% in its net profit at Rs 40.45 crore for the quarter under review as compared to Rs 25 crore for the same quarter in the previous year. Total income of the company increased by 33.31% at Rs 409.43 crore for Q4FY22 as compared Rs 307.12 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported 67.25% rise in its net profit at Rs 154.52 crore as compared to Rs 92.39 crore for the previous year. Total income of the company increased by 24% at Rs 1542.04 crore for year under review as compared to Rs 1243.42 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported 66.36% rise in its net profit at Rs 154.80 crore as compared to Rs 93.05 crore for the previous year. Total income of the company increased by 23.98% at Rs 1543.08 crore for year under review as compared to Rs 1244.65 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.05 |
Dr. Reddys Lab | 1274.25 |
Cipla | 1553.20 |
Lupin | 2184.00 |
Zydus Lifesciences | 1001.85 |
View more.. |